Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

RNC Pharma Database Update: Pharmaceutical Drug Production in Russia (July 2018)

Tuesday, August 28, 2018

Between January and July 2018, Russia produced 186.5 bln RUB worth of pharmaceutical drugs (dispatch prices, VAT included), which is in monetary terms 2.5% higher than that of the same period of 2017. In physical terms, the dynamics are still negative, -10.4%. Over the period, Russia produced around 2.29 bln units of pharmaceuticals.

If calculated in minimum dosage units (MDU), the dynamics are not that negative, -1.9%. Between January and July 2018, Russia produced 38.9 bln MDU. Compared to the first 6 months, the performance in July is the worst, with -15% (in units) and -18% (in MDU).

The dynamics of the Rx production are -12.5% in physical terms, while those of the OTC production are -9%. If calculated in MDU, the dynamics are +3% and -6%, respectively. Among the top 10 EphMRA groups of level two with the highest dispatch volume of OTC drugs in physical terms, seven have negative dynamics. Antivirals, painkillers and cough and cold medicines are among the worst, with -27%, -20% and -16%, respectively.

Among the top 10 producing companies of OTC drugs, Biotec has the best dynamics, with Citramarin, Ascorutin, and Anusol having the highest dynamics (a 14, 7.2 and 6.7 times increase, respectively.) Armavir Biofactory holds the record in the dynamics in physical terms over the period, having increased the production of Naphthyzin in 94 times.

As for Rx drugs, the following categories have the lowest dynamics: solutions for intravenous admission (-54%), anti-infective drugs (-18%), and anti-inflammatory and anti-rheumatics drugs (-16%). Among the top 10 manufacturers, Promomed and Vertex have the highest dynamics in physical terms, having increased its production by 34% and 33%, respectively. Boehringer Ingelheim holds the record, with a 20 times increase. It has been producing only fibrinolytics Actilyse and Metalyse, which are not fully localized. Petrovax (Russia) is responsible for in-bull packaging.

Read more about pharmaceutical drug production in Russia (June results) here:

Dynamics of pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (units) and monetary terms (RUB, VAT included) (January 2017 – July 2018)